Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Public ClinicalTrials.gov record NCT03295877. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Escalation, and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7171009 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD. The study consists of two stages: Single Dose-Escalation (SAD) and Multiple-Dose (MD) stages.
Study identification
- NCT ID
- NCT03295877
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 21, 2017 (Actual)
- Primary completion
- Nov 20, 2018 (Actual)
- Completion
- Nov 20, 2018 (Actual)
- Last update posted
- Feb 12, 2020
2017 – 2018
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Retina Consultants | Bakersfield | California | 93309 | — |
| Northern California Retina Vitreous Associates | Mountain View | California | 94040 | — |
| Retinal Consultants Med Group | Sacramento | California | 95825 | — |
| California Retina Consultants | Santa Barbara | California | 93103 | — |
| California Retina Consultants - Santa Maria | Santa Maria | California | 93454 | — |
| Retina Consultants of Southern Colorado PC; Clinical Research Department | Colorado Springs | Colorado | 80909-1183 | — |
| Florida Eye Associates | Melbourne | Florida | 32901 | — |
| Retina Specialty Institute | Pensacola | Florida | 32503 | — |
| Georgia Retina PC | Marietta | Georgia | 30060 | — |
| The Retina Institute | St Louis | Missouri | 63128 | — |
| Sierra Eye Associates | Reno | Nevada | 89502 | — |
| Western Carolina Retinal Associate PA | Asheville | North Carolina | 28803 | — |
| Tennessee Retina PC. | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03295877, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2020 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03295877 live on ClinicalTrials.gov.